Skip to main content

Table 2 Worm burden reductions (WBRs) following different single oral doses of R, S-PZQ and PZQ

From: In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium

  No. of hamsters cured/treated Mean no. of alive worms ± SD WBR (%) Female WBR (%) ED50 (mg/kg)  
Liver Mesenteric veins Total Females
Control 0/4 2.75 ± 3.8 31.0 ± 9.5 33.8 ± 16.8 15.3 ± 5.2  
PZQ
 250.0 mg/kg 3/4 0.25 ± 0.5 0 0.3 ± 0.5 0 99.3 100   
 200.0 mg/kgb       77.2   118.1
 150.0 mg/kgb       66.1  
 100.0 mg/kgb       39.2  
R-PZQ
 125.0 mg/kg 2/4 0.25 ± 0.5 0.25 ± 0.5 0.5 ± 0.6 0 98.5 100 24.7a  
 62.5 mg/kg 1/4 5.0 ± 4.7 3.25 ± 3.6 8.3 ± 8.1 2.3 ± 3.3 75.6 85.2
 31.0 mg/kg 0/3 6.7 ± 11.5 2.3 ± 2.3 9.0 ± 13.9 4.0 ± 6.9 73.3 73.8
S-PZQ
 500.0 mg/kg 3/4 1.25 ± 2.5 0.75 ± 1.5 2.0 ± 4.0 0 94.1 100 127.6a 5.17c
 250.0 mg/kg 2/4 4.0 ± 4.9 1.75 ± 2.1 5.8 ± 6.9 0 83.0 100
 125.0 mg/kg 0/3 7.0 ± 6.2 11.0 ± 6.0 18.0 ± 12.1 0.7 ± 0.6 46.7 95.6
  1. aDetermined on total worm burden reductions
  2. bData reported by Webbe & James [18]
  3. cEudysmic ratio